ABIVAX Société Anonyme (NASDAQ:ABVX) Shares Gap Up to $13.32

ABIVAX Société Anonyme (NASDAQ:ABVX) gapped up prior to trading on Thursday . The stock had previously closed at $13.32, but opened at $13.93. ABIVAX Société Anonyme shares last traded at $14.01, with a volume of 9,297 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ABVX. Guggenheim started coverage on ABIVAX Société Anonyme in a research note on Monday, April 29th. They set a “buy” rating and a $50.00 price objective for the company. Morgan Stanley lifted their price target on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 11th. Piper Sandler started coverage on shares of ABIVAX Société Anonyme in a research note on Monday, April 29th. They set an “overweight” rating and a $42.00 price objective for the company. Finally, BTIG Research assumed coverage on shares of ABIVAX Société Anonyme in a report on Monday, May 20th. They set a “buy” rating and a $43.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, ABIVAX Société Anonyme has a consensus rating of “Moderate Buy” and an average price target of $34.20.

ABIVAX Société Anonyme Stock Down 2.3 %

The business has a fifty day moving average price of $14.32 and a two-hundred day moving average price of $13.17.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ABVX. BNP Paribas Financial Markets purchased a new position in shares of ABIVAX Société Anonyme during the 1st quarter valued at $81,000. Capstone Investment Advisors LLC purchased a new position in ABIVAX Société Anonyme in the fourth quarter valued at about $618,000. Ghisallo Capital Management LLC acquired a new position in ABIVAX Société Anonyme in the 4th quarter worth about $642,000. Kennedy Capital Management LLC raised its stake in shares of ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after purchasing an additional 31,331 shares in the last quarter. Finally, Rosalind Advisors Inc. acquired a new stake in shares of ABIVAX Société Anonyme during the 1st quarter valued at about $5,411,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.